128940:KRXHanmi Pharm. Co., Ltd. Analysis

Hanmi Pharm. is trading at KRW 496,500, well above the DCF‑derived fair value of roughly KRW 85,730, indicating a material price premium. The stock sits below its 20‑day (KRW 561,200) and 50‑day (KRW 507,720) SMAs while remaining above the 200‑day SMA (KRW 385,042), suggesting short‑term weakness within a longer‑term bullish backdrop. Technical signals reinforce this view: RSI sits at 44 (neutral), MACD is bearish with a negative histogram, and the price is close to the near‑term support level of KRW 464,500. Volatility is high at 85% over the last 30 days, yet beta is low (0.43), implying limited systematic risk. The market sentiment leans toward greed (Fear‑Greed Index 72.9), and the upside potential from the DCF model is modest at about 12.5%.
Fundamentally, revenue growth is flat (0.1%) and operating margins are respectable (14.4%) but the company carries a high debt load (KRW 435.7 bn) with a debt‑to‑equity ratio of 32.4. Cash generation is solid, with operating cash flow of KRW 173.3 bn and a low dividend payout ratio of ~11%, supporting the current 0.4% yield. The pipeline targeting obesity, oncology, and rare diseases could unlock future growth, but the current valuation (forward P/E 28 vs industry 26) remains stretched. Overall, the stock appears overvalued in the near term, while its long‑term prospects hinge on successful product commercialization and debt reduction.